Cbio

What Cbio does

Cbio A/S is a Danish clinical-stage biopharmaceutical company founded in January 2019 that develops next-generation T-cell immunotherapies for patients with late-stage solid tumors. The company's lead product, novoleucel (also referenced as CB-105), is a broad-spectrum tumor-infiltrating lymphocyte (TIL) therapy intended for cancer patients who have exhausted conventional treatment alternatives, with the initial Phase I/IIa trial targeting persistent or recurrent cervical cancer at Karolinska University Hospital in Stockholm following European regulatory clearance received in March 2026. The pipeline additionally targets colorectal, ovarian, kidney, and pancreatic cancers in preclinical development with Odense University Hospital.

The company's core technology is the proprietary REVITA platform, which combines ex-vivo checkpoint inhibition and stimulation with a novel cocktail of stimulators (beyond IL-2) to revitalize resting T-cells and armor them against oxidative stress in the tumor microenvironment. The platform is enabled by an exclusive license from Karolinska Institute, derived from a decade-long collaboration with Prof. Rolf Kiessling's group, and is operationalized through the proprietary Fast Lymphocyte Expansion (FLeX) manufacturing protocol, which reduces production time from 49 to 22 days, increases success rates from 68% to 98%, triples tumor-reactive cell potency, and cuts manual process steps from 2,437 to 378. IP protection extends through 2040. The 1,000 m2 Søborg facility holds ATMP manufacturing authorization with current capacity for up to 150 patients per year, planned to scale to 600.

The business model is commercialization of novoleucel and follow-on TIL therapies to hospitals and cancer treatment centers upon regulatory approval, with the cryopreserved final product formulation designed to enable global distribution. Go-to-market relies on direct engagement with major cancer treatment centers and hospital systems; the company currently operates through academic and hospital partnerships (Karolinska Institute, Karolinska University Hospital, University of Copenhagen BRIC, Odense University Hospital) with Innovation Fund Denmark providing program-level funding support. Revenue is not yet generated; no funding rounds, investors, or capital amounts have been publicly disclosed, and the company appears to remain founder-owned.

Name

Cbio

Legal name

Cbio A/S

Website

https://cbio.dk

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Cbio A/S is a Danish clinical-stage biopharmaceutical company developing next-generation T-cell immunotherapies for late-stage solid tumors. Its lead product novoleucel, based on the proprietary REVITA platform and FLeX manufacturing protocol, targets cervical cancer and four additional solid tumor indications.

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Tumor-infiltrating lymphocytes
• Adoptive cell therapy
• Cancer immunotherapy
• Cell therapy biopharmaceuticals
• Advanced therapy medicinal products

Headquarters

HQ city

Søborg

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. T-cell Therapy Commercialization: Cbio is developing novoleucel, a next-generation T-cell therapy for solid tumors. The company is in early clinical stage with phase I/IIa trial ongoing for cervical cancer. Revenue will be generated through commercialization of therapeutic products to hospitals and cancer treatment centers upon regulatory approval.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Cbio develops and manufactures next-generation T-cell immunotherapies (tumor-infiltrating lymphocyte / TIL-based) for solid tumors, using its proprietary REVITA technology platform that revitalizes T-cells and arms them against oxidative stress. Its lead product, novoleucel (CB-105), is a broad-spectrum autologous T-cell therapy in Phase I/IIa clinical trials targeting late-stage cervical cancer, with preclinical programs in colorectal, ovarian, kidney, and pancreatic cancer.

Product overview

Cbio A/S is a biopharmaceutical company developing next-generation T-cell therapies for solid tumors. The company's portfolio consists of the REVITA Technology Platform as the foundational technology enabling their lead product novoleucel (CB-105), enhanced by the proprietary Fast Lymphocyte Expansion (FLeX) protocol. Novoleucel is a broad-spectrum T-cell therapy designed for late-stage cancer patients, utilizing REVITA's novel checkpoint inhibition and oxidative stress armoring to improve cancer-killing activity. The technology enables treatment from minimally invasive biopsies rather than surgery, with demonstrated improvements in production time, potency, and success rates compared to standard T-cell therapy approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• novoleucel (CB-105) Broad-spectrum next-generation autologous T-cell therapy (TIL-based) designed to target and eradicate tumor cells with reduced opportunities for cancer escape. Targets late-stage cancer patients who have exhausted other treatment alternatives, leveraging Cbio's REVITA technology for improved potency and success rates. Lead indication is cervical cancer, with preclinical programs in colorectal, ovarian, kidney, and pancreatic cancer.
• REVITA Technology Platform Proprietary T-cell therapy technology platform that revitalizes resting immune cells and arms them against oxidative stress, enabling maintenance of killing functionality in hostile tumor microenvironments. Includes ex-vivo checkpoint inhibition and stimulation methods generating a broader T-cell repertoire of more stemness-like T-cells, leaving fewer opportunities for the cancer to escape immune attack.

Quantifiable outcome

• Production time reduced from 49 days to 22 days
• +4 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Karolinska Institute (Prof. Rolf Kiessling's group)coreStrategic or Co-development PartnerCbio collaborates with Prof. Rolf Kiessling's group at Karolinska Institute in Stockholm to advance T-cell therapy to clinical phase I/II testing in cervical cancer patients. Rolf Kiessling is worldwide recognized for early discovery and name-giving of Natural Killer cells. His research on tumor microenvironment and oxidative stress effects on immune cells led to the discovery of how T-cells can be armed against oxidative stress while maintaining effector function.
• University of Copenhagen (BRIC - Krister Wennerberg's group)coreStrategic or Co-development PartnerCbio has established a 3-year research collaboration with Krister Wennerberg's group at the Biotech Research and Innovation Centre, University of Copenhagen. The aim is to improve the TIL therapy product, make the production process more scalable, and potentially further improve Cbio's proprietary TIL stimulator cocktail using high-throughput screening facilities at BRIC. The project is supported by Innovation Fund Denmark through the industry PhD program.
• Odense University HospitalcoreStrategic or Co-development PartnerCbio is collaborating with Odense University Hospital to develop and pre-clinically optimize TIL products for colorectal, kidney, ovarian, and pancreatic cancer patients. The collaboration entails 4 clinical departments as well as the Pathological Institute and is approved by the Ethical Committee from Region South Denmark. The goal is to develop TIL products for these four cancer indications for later clinical testing.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Turnstone Biologics: Clinical-stage biotech developing tumor-infiltrating lymphocyte (TIL) and next-generation selected TIL therapies for solid tumors. Comparable as a TIL-focused peer at similar development stage with autologous cell therapy approach.
• Cellectis: Clinical-stage gene editing and cell therapy company developing allogeneic CAR-T and gene-edited T-cell therapies. Comparable as a cell therapy technology peer with overlapping platform engineering approach to enhance T-cell functionality.
• Allogene Therapeutics: Clinical-stage cell therapy company developing allogeneic ("off-the-shelf") CAR-T therapies for hematologic and solid tumors. Comparable as an adjacent cell therapy peer with differentiated manufacturing model (allogeneic vs Cbio's autologous) targeting similar oncology indications.
• Lyell Immunopharma: Cell therapy company focused on solid tumor TIL and CAR-T programs with proprietary technology to prevent T-cell exhaustion. Partially comparable as a solid tumor cell therapy peer working on T-cell quality and persistence, similar to Cbio's REVITA focus on T-cell fitness.

Broad incumbents

• Novartis (Kymriah): Global pharma with the first commercially approved CAR-T therapy (Kymriah) and broad cell therapy capability. Comparable as a broad incumbent in autologous cell therapy with established manufacturing and commercial infrastructure relevant to Cbio's path to market.
• Gilead Sciences (Kite): Owns Kite Pharma, a leading cell therapy company with approved CAR-T products (Yescarta, Tecartus). Comparable as a broad incumbent in autologous cell therapy for hematologic and solid tumors, representing both a competitor and a potential strategic acquirer/partner for Cbio.

Direct peers

• Iovance Biotherapeutics: Leader in TIL therapy for solid tumors (FDA-approved lifileucel for melanoma) with a maturing commercial-stage platform. Directly comparable to Cbio as a TIL-focused biotech targeting late-stage solid tumors with autologous cell therapy.
• Instil Bio: Clinical-stage TIL therapy company developing ITIL-168 for melanoma and other solid tumors, with in-house manufacturing. Closely comparable to Cbio as a TIL-focused peer in similar clinical development stage with autologous cell therapy approach.
• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing SPEAR T-cell receptor (TCR-T) therapies for solid tumors. Comparable as a peer in the engineered/reengineered T-cell therapy for solid tumors category targeting similar patient populations.
• Tessa Therapeutics: Cell therapy company combining TIL and CAR-T platforms for solid tumors and lymphoma. Comparable as a peer operating in the autologous cell therapy for solid tumors space with similar manufacturing challenges.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cbio-a-s

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cbio